Clinical Trial Update: A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase I clinical trial evaluating the HIV-1 C4-V3 polyvalent peptide vaccine in HIV-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• HIV-1 C4-V3 Polyvalent Peptide Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED